Trusted by Leading Research & Pharma Institutions

Engineering of Mammalian Chassis for Biosynthesis

Unlock the full potential of mammalian cell factories with our cutting-edge chassis engineering platform. From CHO to HEK293 systems, we deliver optimized cell platforms for high-titer production of complex biologics, therapeutic proteins, and next-generation modalities.

CRISPR-Optimized

High Titer Output

GMP-Ready

Learn More

Trusted by leading research and pharmaceutical institutions

Harvard

Pfizer

MIT

Roche

Stanford

Merck

Why Choose Our Platform

Multi-omics guided engineering

Proprietary CHO and HEK293 hosts

Enhanced glycosylation profiles

Scalable from research to GMP

CHO Cell Engineering

GS-knockout and DHFR-negative hosts

HEK293 Platforms

Glyco-engineered for human-like N-glycans

Custom Engineering

Tailored chassis modifications

Service Overview

Comprehensive Mammalian Chassis Engineering Solutions

Our platform combines multi-omics approaches with advanced genome editing to create optimized mammalian cell factories for biopharmaceutical production.

CHO Cell Engineering

Our proprietary CHO chassis platforms have been extensively optimized through multi-omics guided engineering. We offer GS-knockout, DHFR-negative, and custom-modified hosts designed for high-titer production of monoclonal antibodies, bispecifics, and complex fusion proteins.

GS-KO and DHFR-negative hosts available
Enhanced apoptosis resistance

HEK293 Glyco-Engineering

Our glyco-engineered HEK293 platforms produce proteins with human-like N-glycosylation profiles. CRISPR-based knockout of GalNAc transferases combined with overexpression of therapeutic-relevant sialyltransferases enables superior pharmacokinetic properties.

Human-like glycan profiles
Improved half-life and clearance
Sialic acid optimization

Multi-Omics Guided Design

Integration of genomics, transcriptomics, and proteomics data for rational chassis optimization.

Deep Sequencing QC

Complete genomic characterization of engineered cell lines with targeted locus amplification.

Scalable Platforms

Seamless scale-up from research cell banks to GMP manufacturing.

Technology Platform

Advanced Engineering Technologies

Industry-leading tools for precise and efficient mammalian cell chassis modification.

CRISPR/Cas9 Engineering

State-of-the-art RNP-based delivery for high-efficiency genome editing. Support for multiplexed knockout, knock-in, and base editing in both CHO and HEK293 systems.

Up to 10-gene multiplex knockout
RNP delivery for minimal off-target effects
Seamless HDR knock-in capability

Multi-Omics Integration

Genome-scale metabolic modeling combined with transcriptomic and proteomic profiling to identify and target key bottlenecks in protein production.

iCHO genome-scale models
Flux balance analysis
Systems biology guided design

Transposon Systems

PiggyBac and Sleeping Beauty transposon technologies for stable, high-level transgene integration at transcriptionally active genomic loci.

Large cargo capacity (up to 15 kb)
Site-specific integration
Stable expression over 100+ passages

Glycosylation Engineering

Precise manipulation of glycosylation pathways through CRISPR-based knockout of unwanted glycosyltransferases and overexpression of therapeutic-relevant enzymes. Achieve consistent, homogeneous glycan profiles for improved product quality.

B4GALNT3/4 KO ST6GAL1 Overexpression GnT-I/II Engineering

Cell Cycle Engineering

Decouple growth and production phases through targeted cell cycle control. Engineering of CDK inhibitors and proliferation pathways enables higher specific productivity without compromising cell growth characteristics.

p21/p27 Engineering CDK4/6 Modulation Growth-Production Decoupling

Technical Specifications

Platform Capabilities

Comprehensive service specifications for mammalian chassis engineering projects.

CHO Cell Platforms

Host Cell Lines CHO-K1, CHO-S, DG44 derivatives

Selection Systems GS-KO, DHFR-negative, antibiotic selection

Transgene Integration PiggyBac, Sleeping Beauty, random integration

Glycosylation Human-like, defined profiles available

Scalability 1 mL to 20,000 L bioreactors

HEK293 Platforms

Host Cell Lines HEK293, HEK293F, FreeStyle 293-F

Glyco-Engineering GalNAc KO, enhanced sialylation

Transfection PEI, electroporation, viral vectors

Expression Format Transient and stable pools

Quality & Regulatory Compliance

99%+

Monoclonality Assurance

100+

Generations Stability

GMP

Manufacturing Ready

IND

Filing Support

Service Workflow

End-to-End Development Process

Streamlined pipeline from chassis selection to GMP-ready cell bank.

Step 1

Project Consultation & Design

Comprehensive assessment of your target molecule, desired product quality attributes, and regulatory requirements. Our scientific team develops a customized engineering strategy.

Step 2

Host Selection & Engineering

Selection of optimal CHO or HEK293 chassis. Application of CRISPR-based engineering, glyco-engineering, or pathway optimization as required by project goals.

Step 3

Screening & Clone Selection

High-throughput screening using automated platforms. Single-cell cloning with imaging verification. Assessment of productivity, growth, and product quality.

Step 4

Stability & Scale-Up

Extended stability studies across multiple passages. Process development for scale-up. Generation of research cell banks and initiation of GMP production preparation.

Step 5

Cell Bank & Delivery

Generation of MCB and WCB under GMP conditions. Complete characterization including genomic stability, identity, and purity testing. Regulatory documentation package.

Applications

Therapeutic & Research Applications

Our mammalian chassis platforms support diverse product modalities and applications.

Monoclonal Antibodies

High-productivity CHO chassis optimized for IgG production with consistent quality attributes.

Defined glycosylation profiles
Low aggregation and high purity
GMP cell banks available

Bispecific Antibodies

Specialized platforms for challenging bispecific formats requiring precise assembly and quality control.

Multiple format compatibility
Enhanced assembly efficiency
Fragment-free production
ADCC-optimized variants

Fc-Fusion Proteins

Optimized secretion pathways and improved folding for complex Fc-fusion constructs.

High secretion efficiency
Proper disulfide bond formation
Consistent glycan profiles
Extended half-life characterization

Cytokine Fusion Proteins

Enhanced stability and activity for cytokine-based therapeutics.

Improved protein stability
Optimized bioactivity
Reduced aggregation
PK/PD characterization

Therapeutic Glycoproteins

Human-like N-glycosylation for improved pharmacokinetics and reduced immunogenicity.

Defined glycan structures
Consistent sialylation levels
Low non-human glycan content
GMP glycan analysis

Glyco-Engineered Products

Custom glycan profiles for specific therapeutic requirements.

GalNAc-free production
Enhanced sialylation
Core-fucosylated variants
Custom glycan engineering

Membrane Proteins

Specialized expression strategies for challenging membrane protein targets.

GPCR optimization
Ion channel production
Transporter engineering
Solubilization protocols

Multi-Subunit Complexes

Co-expression systems for complex therapeutic proteins.

Balanced expression systems
Proper subunit assembly
Quality control for complexes
Structural biology grades

Testimonials

What Our Partners Say

"The glyco-engineering capabilities transformed our therapeutic protein program. The human-like glycan profile significantly improved half-life in preclinical studies."

Research Institution

Protein Engineering Team

"Achieving 8 g/L titers with their CHO platform accelerated our IND timeline significantly. The cell line stability exceeded our expectations across 90+ passages."

Biotechnology Company

Manufacturing Sciences

"The CRISPR multiplexing capability allowed us to knock out five genes simultaneously. This would have taken months with conventional approaches."

Pharmaceutical Company

Cell Line Development

Scientific Literature

Supporting Research

Peer-reviewed publications supporting our mammalian chassis engineering platform.

Citations

Cell factory engineering: Challenges and opportunities for synthetic biology applications

Bachhav B, de Rossi J, Llanos CD, Segatori L. Biotechnology and Bioengineering. 2023.

This comprehensive review discusses advances in mammalian cell engineering and synthetic biology approaches for biomanufacturing of therapeutic proteins.

View DOI

Citations

Glyco-engineered HEK 293-F cell lines for the production of therapeutic glycoproteins with human N-glycosylation

Uhler R, Popa-Wagner R, Kröning M, et al. Glycobiology. 2021.

CRISPR-based glyco-engineering of HEK293 cells to eliminate terminal GalNAc and enhance sialylation for improved therapeutic protein pharmacokinetics.

View DOI

Citations

An Omic's Data-Driven Approach Towards Engineering Mammalian Cell Factories

Torres M, Ortuzar V, Dickson AJ, Hussain H. Cell Engineering (Springer). 2022.

Multi-omics integration for understanding cellular bottlenecks and rational design of improved mammalian cell factories for biopharmaceutical production.

View DOI

Citations

Decoupling Growth and Protein Production in CHO Cells: A Targeted Approach

Frontiers in Bioengineering and Biotechnology. 2021.

Synthetic biology approaches for targeted cell cycle control to improve specific productivity in CHO cells without compromising cell growth.

View DOI

Citations

A ribonucleoprotein-based decaplex CRISPR/Cas9 knockout strategy for CHO host engineering

Carver J, Kern M, Ko P, et al. Biotechnology Progress. 2022.

Efficient multiplexed gene editing in CHO cells using RNP delivery for simultaneous knockout of up to 10 genes.

View DOI

FAQ

Frequently Asked Questions

What mammalian cell platforms do you offer?

We offer comprehensive platforms including CHO-K1, CHO-S, DG44 derivatives, and HEK293/HEK293F cell lines. Our CHO platforms feature GS-knockout and DHFR-negative selection systems, while HEK293 platforms include glyco-engineered variants for human-like N-glycosylation.

What titers can be achieved with your CHO platform?

Our optimized CHO platforms routinely achieve titers of 5-8 g/L in fed-batch cultures, with demonstrated titers exceeding 10 g/L for standard IgG formats. Specific productivity depends on the protein sequence, glycosylation requirements, and process conditions.

How long does cell line development take?

Standard timelines: stable pools in 4-8 weeks, research cell banks in 10-14 weeks, and GMP-ready cell banks in 16-20 weeks from project start. Expedited timelines are available for urgent projects.

What glyco-engineering options are available?

We offer comprehensive glyco-engineering including: GalNAc transferase knockout (B4GALNT3/4), sialyltransferase overexpression (ST6GAL1, ST3GAL6), GnT-I/II engineering, and core-fucosylation control. Custom glycan profiles can be designed for specific therapeutic requirements.

Do you support IND filing?

Yes, we provide comprehensive IND filing support including: cell bank characterization data, clone history and provenance, genomic stability documentation, and all required regulatory documentation. Our platform has supported numerous successful IND submissions globally.

What quality control is performed on cell lines?

Comprehensive QC includes: genomic stability assessment, targeted locus amplification (TLA) for transgene characterization, mycoplasma testing, identity verification, purity testing, and productivity/stability studies across multiple passages.

Can you engineer difficult-to-express proteins?

Yes, we specialize in engineering solutions for challenging targets. Our approaches include: secretion pathway optimization, chaperone co-expression, disulfide bond engineering, cell cycle decoupling, and growth/production phase separation strategies.

What is your approach to clone stability?

We ensure stability through: site-specific integration using transposon systems, characterization across 60-90 passages, genomic stability assessment via WGS, and selection of clones with stable transgene copy numbers and expression profiles.

What scalability options are available?

Our platforms scale seamlessly from 1 mL shake flask to 20,000 L bioreactors. We provide process development support for scale-up, including media optimization, feed strategy development, and bioreactor parameter translation.

Do you offer custom engineering beyond standard platforms?

Absolutely. We provide bespoke engineering services including: custom pathway modifications, apoptosis engineering, metabolic flux optimization, and novel selection system development. Contact us to discuss your specific requirements.

Ready to Start Your Project?

Get a customized quote for your Mammalian Chassis Engineering project. Our experts will respond within 24 hours.

No obligation

24h response

Expert consultation

Request a Quote

Engineering of Mammalian Chassis for Biosynthesis

Why Choose Our Platform

CHO Cell Engineering

HEK293 Platforms

Custom Engineering

Comprehensive Mammalian Chassis Engineering Solutions

CHO Cell Engineering

HEK293 Glyco-Engineering

Multi-Omics Guided Design

Deep Sequencing QC

Scalable Platforms

Ready to Engineer Your Mammalian Chassis?

Advanced Engineering Technologies

CRISPR/Cas9 Engineering

Multi-Omics Integration

Transposon Systems

Glycosylation Engineering

Cell Cycle Engineering

Platform Capabilities

CHO Cell Platforms

HEK293 Platforms

Quality & Regulatory Compliance

End-to-End Development Process

Project Consultation & Design

Host Selection & Engineering

Screening & Clone Selection

Stability & Scale-Up

Cell Bank & Delivery

Therapeutic & Research Applications

Monoclonal Antibodies

Bispecific Antibodies

Fc-Fusion Proteins

Cytokine Fusion Proteins

Therapeutic Glycoproteins

Glyco-Engineered Products

Membrane Proteins

Multi-Subunit Complexes

What Our Partners Say

Supporting Research

Cell factory engineering: Challenges and opportunities for synthetic biology applications

Glyco-engineered HEK 293-F cell lines for the production of therapeutic glycoproteins with human N-glycosylation

An Omic's Data-Driven Approach Towards Engineering Mammalian Cell Factories

Decoupling Growth and Protein Production in CHO Cells: A Targeted Approach

A ribonucleoprotein-based decaplex CRISPR/Cas9 knockout strategy for CHO host engineering

Frequently Asked Questions

Ready to Start Your Project?

Recommended Services

Related Resources